The National Institute for Health and Care Excellence (NICE) has updated its guidance, recommending a targeted therapy for patients in England with advanced bowel cancer. The decision, which reverses earlier draft guidance, means that bevacizumab, in combination with chemotherapy, will now be an option for individuals whose cancer has spread and who have a RAS wild-type tumour.
This reversal follows an appeal process and further evaluation of the evidence, highlighting the rigorous assessment undertaken by NICE before finalising its recommendations. The initial draft guidance had not recommended the treatment, leading to concerns among patient groups and clinicians about access to vital therapies. The new recommendation is expected to offer a significant new treatment pathway for eligible patients.
Bowel cancer, also known as colorectal cancer, is a major health concern in the UK. It is the fourth most common cancer, with approximately 42,900 new cases diagnosed each year. Furthermore, it is the second deadliest cancer, causing around 16,500 deaths annually. Early diagnosis and access to effective treatments are crucial for improving patient outcomes.
The targeted therapy works by inhibiting the growth of new blood vessels that tumours need to grow and spread. This mechanism makes it particularly effective in slowing the progression of advanced cancers. The specific eligibility criteria — advanced cancer that has spread and a RAS wild-type tumour — ensure that the treatment is directed to patients most likely to benefit, optimising resource allocation within the NHS.
This positive development is anticipated to impact approximately 5,500 people in England each year who meet the criteria for this treatment. It represents a crucial step forward in providing more comprehensive and effective care for those living with advanced bowel cancer, potentially improving quality of life and extending survival for this patient group.
The decision underscores NICE's commitment to ensuring that the NHS provides access to clinically effective and cost-effective treatments, balancing innovation with the sustainable use of public funds. The process of reviewing and updating guidance based on new evidence and stakeholder feedback is a cornerstone of how new medicines become available to patients in the UK.